As of the latest Form 4 filed May 26, 2026.
What Amylyx Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 29 most recent filings for AMLX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | 2026-05-21 | Firestone Karen Director | PPurchase | +3.80K | $13.51 | $51.3K | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-05 | Cohen Joshua B Co-Chief Executive Officer | AAward | +249K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-05 | Mazzariello Gina Chief Legal Officer | AAward | +74.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-05 | FRATES JAMES M Chief Financial Officer | AAward | +96.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-05 | Klee Justin B. Co-Chief Executive Officer | AAward | +249K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-09 | 2026-03-05 | Bedrosian Camille L Chief Medical Officer | AAward | +96.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Klee Justin B. Co-Chief Executive Officer | SSale | −29.3K | $14.47 | $424K | No | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Cohen Joshua B Co-Chief Executive Officer | SSale | −29.3K | $14.48 | $424K | No | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Bedrosian Camille L Chief Medical Officer | SSale | −6.46K | $14.58 | $94.2K | No | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | FRATES JAMES M Chief Financial Officer | SSale | −7.91K | $14.52 | $115K | No | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Mazzariello Gina Chief Legal Officer | SSale | −6.84K | $14.52 | $99.4K | No | Form 4 ↗ |
| 2026-02-25 | 2026-02-23 | Mazzariello Gina Chief Legal Officer | SSale | −3.42K | $14.14 | $48.4K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | FRATES JAMES M Chief Financial Officer | SSale | −3.56K | $14.65 | $52.1K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Cohen Joshua B Co-Chief Executive Officer | SSale | −15.5K | $14.68 | $228K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Mazzariello Gina Chief Legal Officer | SSale | −3.45K | $14.65 | $50.5K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Klee Justin B. Co-Chief Executive Officer | SSale | −15.5K | $14.69 | $228K | No | Form 4 ↗ |
| 2026-01-20 | 2026-01-16 | Cohen Joshua B Co-Chief Executive Officer | SSale | −1.97K | $13.83 | $27.3K | No | Form 4 ↗ |
| 2026-01-20 | 2026-01-16 | Cohen Joshua B, Co-Chief Executive Officer | MExercise | +2.82K | $7.57 | $21.3K | No | Form 4 ↗ |
| 2026-01-20 | 2026-01-16 | Klee Justin B. Co-Chief Executive Officer | SSale | −2.00K | $13.89 | $27.7K | No | Form 4 ↗ |
| 2026-01-20 | 2026-01-16 | Klee Justin B., Co-Chief Executive Officer | MExercise | +2.85K | $7.57 | $21.6K | No | Form 4 ↗ |
| 2026-01-20 | 2026-01-15 | Cohen Joshua B Co-Chief Executive Officer | SSale | −136K | $13.59 | $1.85M | No | Form 4 ↗ |
| 2026-01-20 | 2026-01-15 | Cohen Joshua B, Co-Chief Executive Officer | MExercise | +197K | $7.57 | $1.49M | No | Form 4 ↗ |
| 2026-01-20 | 2026-01-15 | Klee Justin B. Co-Chief Executive Officer | SSale | −136K | $13.58 | $1.85M | No | Form 4 ↗ |
| 2026-01-20 | 2026-01-15 | Klee Justin B., Co-Chief Executive Officer | MExercise | +197K | $7.57 | $1.49M | No | Form 4 ↗ |
| 2026-01-14 | 2026-01-12 | MILNE GEORGE M JR Director | GGift | −17.8K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | FRATES JAMES M Chief Financial Officer | SSale | −3.33K | $11.11 | $37.0K | No | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | Cohen Joshua B Co-Chief Executive Officer | SSale | −7.71K | $11.09 | $85.6K | No | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | Klee Justin B. Co-Chief Executive Officer | SSale | −7.71K | $11.09 | $85.6K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-23 | Firestone Karen Director | PPurchase | +8.10K | $12.45 | $101K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also AMLX’s full analysis or the market-wide insider trading feed. The tabs above jump to AMLX’s other SEC data.
Source: SEC Form 4 filings for AMLX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.